Home
Profile
Manufacturing
Quality Control
Products
  Contact Us Careers Sitemap          
   
 
:: Research & Development
:: International Collaboration
:: Business Opportunities
:: Latest Events
:: Divisions At a Glance


  press_release_btn_otherspg :: Press Releases vline_separator

  :: In Licensing   inlicensing_btn__otherspg vline_separator

  outlicensing_btn_otherspg :: Out Licensing vline_separator

 
  Cytarabine Injection BP 100 mg
  Indications :
 

Induction and maintenance of remission in acute myelocytic leukaemia of both adults & children.

Acute lymphocytic leukaemia

Chronic myelocytic leukaemia (Blast Phase)

Non-Hodgkin's lymphoma

Meningeal leukaemia

Malignant pleural effusions

Multiple Myeloma

Myelodysplastic syndrome

Leucoencephalopathy

   
  Dosage :
  Normal adult dosage : Doses of upto 200mg/m2 daily as a continuous IV infusion over 24 hours for 5 days. Total 1000mg/m2.

Single agent therapy : IV infusion for five days (120 hours) repeated at approximately two weekly intervals.

Meningeal Leukaemia : Intrathecally 5 mg/m2 to 75 mg/m2 body surface area OD for 4 days to once every 4 days.

Combination Therapy : 100 to 200 mg/m2 per day by continuous IV infusion (days 1 to 7) or 100 mg/m2 IV every 12 hrs (days 1-7).

Dosage Adjustment :

Renal Impairment : Not Necessary.

Hepatic Impairment : Required.
   
  Packing : 10 Vials of 100 mg
 



  Home | Careers | Site map | Contact Us



 
  All contents copyright © United Biotech (P) Limited, All rights reserved.